NOV 18·Zacks CommentaryMed
What Makes Jade Biosciences, Inc. ( JBIO ) a New Buy Stock
Jade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
StockHealthcare · BIOTECHNOLOGY
$JBIO
Jade Biosciences, Inc.
Price · $JBIOvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $JBIO in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $JBIO in the last 30 days.
Top stories · $JBIOMore →
NOV 18·Zacks Commentary
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. ( JBIO ) : Here's What You Should Know
The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 52.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NOV 8·GlobeNewswire
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 ( GLOBE NEWSWIRE ) -- Jade Biosciences, Inc. ( "the Company" or "Jade" ) , ( Nasdaq: JBIO ) , a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for ...